jp-filings
Back to company search

4595

MIZUHO MEDY CO.,LTD.

ミズホメディー

Industry
Pharmaceutical
Market
Standard
Accounting standards
Japanese GAAP
Consolidation basis
Non-consolidated

Notes

  • Stock adjustments
    Jul 1, 2024 Stock split 1 share → 2 shares

Key metrics

Revenue(million JPY)

Dec 2021
13,137
Dec 2022
17,582
Dec 2023
10,990
Dec 2024
11,429
Dec 2025
11,260

Operating profit(million JPY)

Dec 2021
6,698
Dec 2022
11,104
Dec 2023
5,152
Dec 2024
4,917
Dec 2025
4,646

Operating profit margin(%)

Dec 2021
50.99
Dec 2022
63.16
Dec 2023
46.88
Dec 2024
43.02
Dec 2025
41.26

Profit before tax(million JPY)

Dec 2021
6,825
Dec 2022
11,071
Dec 2023
5,292
Dec 2024
5,167
Dec 2025
4,736

Profit(million JPY)

Dec 2021
4,817
Dec 2022
7,838
Dec 2023
3,774
Dec 2024
3,773
Dec 2025
3,425

Total assets(million JPY)

Dec 2021
12,193
Dec 2022
19,102
Dec 2023
18,948
Dec 2024
20,729
Dec 2025
22,375

Cash and cash equivalents(million JPY)

Dec 2021
4,327
Dec 2022
7,375
Dec 2023
8,716
Dec 2024
9,664
Dec 2025
2,259

Cash flows from operating activities(million JPY)

Dec 2021
5,597
Dec 2022
6,173
Dec 2023
3,992
Dec 2024
3,348
Dec 2025
1,956

Cash flows from investing activities(million JPY)

Dec 2021
-160
Dec 2022
-1,554
Dec 2023
-270
Dec 2024
-307
Dec 2025
-7,284

Cash flows from financing activities(million JPY)

Dec 2021
-1,165
Dec 2022
-1,571
Dec 2023
-2,381
Dec 2024
-2,094
Dec 2025
-2,077

Return on equity(%)

Dec 2021
81.6
Dec 2022
70.3
Dec 2023
25.2
Dec 2024
22.9
Dec 2025
19

Equity ratio(%)

Dec 2021
65.8
Dec 2022
74.8
Dec 2023
82.7
Dec 2024
83.7
Dec 2025
83.5

Earnings per share(JPY per share)

Dec 2021
252.865
Dec 2022
411.47
Dec 2023
198.135
Dec 2024
198.12
Dec 2025
179.84

Net assets per share(JPY per share)

Dec 2021
421.475
Dec 2022
749.79
Dec 2023
822.93
Dec 2024
911.05
Dec 2025
980.89

Dividend per share(JPY per share)

Dec 2021
77.5
Dec 2022
125
Dec 2023
100
Dec 2024
100
Dec 2025
100

Payout ratio(%)

Dec 2021
30.65
Dec 2022
30.38
Dec 2023
50.47
Dec 2024
50.47
Dec 2025
55.6

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.